About us

Angelini Research & Development

Angelini has over 40 years experience in the R&D of small pharmaceuticals molecules, spanning from drug discovery to regulatory filing. Several proprietary drugs have been fully developed by Angelini and two of them have gained the status of global products, marketed worldwide in more than 60 countries: the topical anti-inflammatory benzydamine (cytokine suppressant anti-inflammatory drug - “CSAID”) and the antidepressant trazodone (Serotonin Antagonist and Reuptake Inhibitor - “SARI”). In more recent times, Angelini, under license from Nippon Shinyaku, fully developed the antibacterial prulifloxacin, a fluoroquinolone, for the European market.
Besides actively pursuing the development of its pipeline, Angelini is highly interested in opportunities for the in-licensing of new projects and products and looks for opportunities of collaboration ranging from R&D partnership to out-licensing. At present Angelini R&D is engaged in the development of new drugs, the finding of new indications for already marketed drugs and the extension of its line of products.

 

Angelini R&D covers the complete spectrum of research activities: from Discovery of new pharmacologically active chemicals to the Preclinical Development of leads compounds by means of formal toxicological and ADME studies, to their Clinical Development through phase I – phase III clinical studies in order to obtain the evidence of efficacy and safety required for registration.
These activities are performed at the Angelini Research Center and at primary private and public institutions by collaborating with leading scientists worldwide.

top
Angelini's Reasearch milestones:

Oxolamina cough suppressant
Benzydamine anti-inflammatory drug
Trazodone anti-depressant agent
Bendaline anticataract agent
Dapiprazole antiglaucoma preparation
Prulifloxacin antibacterial agent

top

Angelini R&D Pipeline

Clinical Stage


  • BINDARIT: a MCP-1/CCL2 production inhibitor. - Indications: Diabetic Nephropathy Phase II completed and Restenosis Phase II ongoing.
  • TRAZODONE: a SARI Antidepressant. Improved “Once a Day” formulation with Labopharm Contramid® Technology. FDA Approved Feb 2010
  • PRULIFLOXACIN: an antibacterial fluoroquinolone. New Indications Acute Bacterial Rhino Sinusitis – ABRS. Phase III.
  • p40 INHIBITOR : topical formulation. - Indication: psoriasis - Phase II

Preclinical Stage

  • MCP-1/CCL2 & SELECTED CYTO KINES PRODUCTIONS INHIBITORS - Therapeutic potential: breast & prostate metastatic cancer; inflammatory and neuropathic pain; IBD (Inflammatory Bowel Disease); uveitis
  • AF3485: mPGES-1 inhibitors - Therapeutic potential: inflammatory pain & oncology
  • AF3473: 5-HT4 antagonist with no hERG liabilities - Therapeutic potential: neuropathic pain
  • Peroxisome Proliferator Activated Receptor gamma (PPARgamma) modulators – Therapeutic potential: inflammation, atherosclerosis, diabetes
  • Glycogen synthase kinase-3 ß (GSK-3ß) inhibitor – Therapeutic potential: neurodegenerative diseases and inflammatory disorders
  • Selected HIT/LEAD from Angelini Chemical Library – Targets: 5-HT2A receptor; Poly ADP-ribose polymerase; Dipeptidyl peptidase IV; Aldose reductase; Epidermal growth factor receptor (EGFR)

Biopolymers

  • POLGLUMYT®: Bio-Polymers for drug delivery (oral and ophthalmic preparations)

top
Not Just Pharmaceuticals: All-Around Innovation

Innovation is an integral part of the on-going development of each Angelini parapharmaceutical. This includes personal care and hygiene products which, although not strictly speaking pharmaceuticals, are the result of intensive research and development activities. Product and technology research is of fundamental importance and enables the Angelini Group to keep its products at the cutting edge of development.
Fater, the joint venture between the Angelini Group and Procter&Gamble, promotes research into fine chemicals, manufacturing technologies and consumption trends. The Company’s focus on innovation has been intensified thanks to the complementary but different backgrounds of the two partners: international in the case of Procter&Gamble and with strong local roots in Italy in the case of Angelini. In its technological process development activities, the Angelini Group can also draw on the resources of Fameccanica.Data, another joint venture with Procter&Gamble whose activities in the design and implementation of production lines and automation systems are intended to foster synergies within the Angelini Group.

 top

Torna su

Products & Medicines

Search